Research map: Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC

Back to the article

Papers in this map

  1. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells · Daniel W. Lee · 2018 · 3668 citations · Cited by this paper
  2. Real-World Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicentre Study · 2026 · Related
  3. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer · Leora Horn · 2018 · 3642 citations · Cited by this paper
  4. Next-Generation Sequencing Completion and Timeliness Using a Reflex Testing Protocol for Patients with Stage II to IV Nonsquamous Non–Small Cell Lung Cancer · 2026 · Related
  5. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial · Luis G Paz-Ares · 2019 · 2314 citations · Cited by this paper
  6. Brief Report: A Pilot Study Evaluating the Feasibility, Safety, and Compliance With a Fasting-Mimicking Diet in Patients With Metastatic Non–Small Cell Lung Cancer · 2026 · Related
  7. Small-cell lung cancer · Charles M. Rudin · 2021 · 1631 citations · Cited by this paper
  8. Complete Spontaneous Regression of Lung Adenocarcinoma With No Residual Malignancy After Surgical Resection: A Case Report · 2026 · Related
  9. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo · Laura R. Saunders · 2015 · 606 citations · Cited by this paper
  10. Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non–Small Cell Lung Cancer: A Nationwide C CAT Cohort From Japan · 2026 · Related
  11. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer · Myung‐Ju Ahn · 2023 · 580 citations · Cited by this paper
  12. Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group · 2026 · Related
  13. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study · Charles M. Rudin · 2016 · 579 citations · Cited by this paper
  14. Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma · 2026 · Related
  15. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology · Apar Kishor Ganti · 2021 · 494 citations · Cited by this paper
  16. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State · 2026 · Related
  17. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial · José Manuel Trigo · 2020 · 488 citations · Cited by this paper
  18. Adjuvant Therapy After Pathologic Complete Response to Neoadjuvant Immunochemotherapy in Non–Small Cell Lung Cancer: A Multicenter Retrospective Real-World Study · 2026 · Related
  19. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. · Kathy S. Albain · 1990 · 389 citations · Cited by this paper
  20. Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR · Xinran Ma · 2020 · 367 citations · Cited by this paper
  21. Tumour burden and efficacy of immune-checkpoint inhibitors · Filippo Gustavo Dall’Olio · 2021 · 357 citations · Cited by this paper
  22. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study · Luis G Paz-Ares · 2023 · 338 citations · Cited by this paper
  23. Metabolic Tumor Burden Predicts for Disease Progression and Death in Lung Cancer · Percy Lee · 2007 · 192 citations · Cited by this paper
  24. Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States · Qianyi Zhang · 2021 · 172 citations · Cited by this paper
  25. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma · James A. Davis · 2023 · 47 citations · Cited by this paper
  26. Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use · Utsav Joshi · 2025 · 7 citations · Cited by this paper
  27. Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer · Alissa Jamie Cooper · 2026 · 4 citations · Cited by this paper
  28. Predictive markers of response and toxicity to tarlatamab in patients with extensive stage small cell lung cancer (ES-SCLC): A multi-institutional real-world analysis. · Graeme Fenton · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)